Presbia offers an innovative solution for individuals suffering from presbyopia through its Flexivue Microlens™ technology. This advanced ophthalmic treatment involves the implantation of a 3-mm diameter lens into the non-dominant eye, utilizing a precise 150 kHz femtosecond laser to create a corneal pocket. Unlike traditional methods such as reading glasses or contact lenses, the Flexivue Microlens™ provides a more permanent and effective correction for near vision, allowing patients to read common items like cell phone messages and restaurant menus without the hassle of switching glasses. Clinical studies have shown significant improvements in near vision, with patients experiencing enhanced visual acuity shortly after the procedure.

The Flexivue Microlens™ is designed to be easily removable and upgradable, accommodating changes in a patient's vision over time. This flexibility sets it apart from other treatments, such as monovision LASIK or intraocular lens replacement surgery, which may be more invasive. With a reported 97% patient satisfaction rate, the technology has demonstrated its effectiveness in improving near vision while maintaining stable results over a year post-implantation. Presbia's commitment to advancing ophthalmic solutions positions the Flexivue Microlens™ as a promising option for those seeking freedom from reading glasses.

United States

Presbia is a medical device company focused on the development of the presbyopia-correcting Presbia Flexivue Microlens™ – an innovative solution for the common age-related loss of the ability to read or focus on near objects. The 3mm diameter lens is implanted in a corneal pocket created by a femtosecond laser.

Presbia

Company Details